Schott Pharma stock advances on strong annual sales and margin

Schott Pharma (DE000A3ENQ51) is backed by fiscal 2025 sales of EUR 957 million and an adjusted EBITDA margin of 25.3%, while the Pharmaceuticals segment posted 33.5% revenue growth in the same year. The company also reported net cash from operating activities of EUR 184 million in fiscal 2025, a metric that underlines cash generation.

Revenue up 13.2%

Schott Pharma reported fiscal 2025 sales of EUR 957 million, up 13.2% from the prior year, according to the companys annual reporting figures used here as the latest available operating base. Adjusted EBITDA reached EUR 242 million, with the 25.3% margin showing that profitability remained high even as the business expanded.

The comparison matters because the prior-year sales base was EUR 846 million, so the increase was EUR 111 million. Net cash from operating activities was EUR 184 million in fiscal 2025, giving investors a second dated cash metric alongside the margin figure.

Pharmaceuticals grows 33.5%

The pharmaceuticals business generated EUR 696 million in fiscal 2025, up 33.5% year on year, and accounted for the largest share of group revenue. That mix shift is the clearest operating number in the latest annual profile because it shows where Schott Pharma is concentrating growth.

The same reporting base shows that annual adjusted EBITDA of EUR 242 million translated into an operating margin of 25.3%, which is unusually useful for a packaging and consumables business. For investors, the question is less about product breadth and more about whether that margin can hold while revenue expands.

Pharmaceuticals as growth engine

Schott Pharma says the Pharmaceuticals segment is its main growth engine, and the fiscal 2025 figure of EUR 696 million makes that visible in the accounts. A 33.5% increase in one year is far ahead of group growth and explains why the segment mix is moving toward higher-value applications.

The margin backdrop is equally important. With adjusted EBITDA at EUR 242 million and a 25.3% margin in fiscal 2025, the company entered the new reporting cycle with a stronger profit base than the revenue line alone suggests.

Product line and use case

Schott Pharma focuses on glass and polymer primary packaging for injectable drugs, and that portfolio is the commercial link behind the numbers above. The product set matters because demand is tied to fill-finish activity, biologics, and drug delivery systems rather than a single consumer cycle.

That makes the annual mix shift relevant for investors even without a fresh trading update: a business with EUR 957 million in sales, EUR 242 million in adjusted EBITDA, and EUR 184 million in operating cash flow has a clear numerical profile that can be measured against future quarters.

Trading level to watch

Schott Pharma shares were last priced at EUR 0.00 as of 24 July 2026 at 09:43 UTC in this article build. The fact box below carries the same as-of convention for consistency with the editorial body.